Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα(q) and Gα(11) and kill uveal melanoma cells

There is no efficacious standard of care therapy for uveal melanoma. Unlike cutaneous disease, uveal melanoma does not exhibit RAS mutations but instead contains mutations with ~90% penetrance in either Gα(q) or Gα(11). Previously we demonstrated that neratinib caused ERBB1/2/4 and RAS internalizati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Biol Ther
Hlavní autoři: Booth, Laurence, Roberts, Jane L., Sander, Cindy, Lalani, Alshad S., Kirkwood, John M., Hancock, John F., Poklepovic, Andrew, Dent, Paul
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606002/
https://ncbi.nlm.nih.gov/pubmed/30571927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1551747
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky